title: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience.
abstract: BACKGROUND
  The objective of this study was to assess the outcome of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) plus early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gynecological malignancies.
  
  
  METHODS
  A retrospective series of 51 patients with advanced gynecologic cancer, evaluated between May 2008 to February 2014. Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction (CCR) score were used in the study group. The study group consisted of the cancers of ovarian, fallopian tube, endometrial, and uterine sarcomas.
  
  
  RESULTS
  Mean PCI score of the study group was 18, and the postoperative complications were similar with the literature. Patients were followed in a period of 15 days to 64 months and the mean survival time was 22.8 months. Fifty-two percent of the patients were alive without evidence of the disease and overall one-year survival was found 56%.
  
  
  CONCLUSIONS
  The authors concluded that CRS, HIPEC, EPIC, and peritonectomy are a crucial options in patients with advanced gynecological cancers.
authors.forename: K
authors.initials: K
authors.lastname: Karadayi
authors.forename: C
authors.initials: C
authors.lastname: Yildiz
authors.forename: S
authors.initials: S
authors.lastname: Karakus
authors.forename: O Bozoklu
authors.initials: OB
authors.lastname: Akkar
authors.forename: G Pakay
authors.initials: GP
authors.lastname: Ugurlu
authors.forename: A
authors.initials: A
authors.lastname: Kurt
authors.forename: A
authors.initials: A
authors.lastname: Yanik
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000556:secondary / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D015331:Cohort Studies; D065426:Cytoreduction Surgical Procedures / Q000379:methods*; D016889:Endometrial Neoplasms / Q000473:pathology / Q000628:therapy*; D005185:Fallopian Tube Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007263:Infusions, Parenteral; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy*; D012189:Retrospective Studies; D012509:Sarcoma / Q000556:secondary / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000473:pathology / Q000628:therapy; D055815:Young Adult
chemical_list: D017239:Paclitaxel; D002945:Cisplatin